Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy

Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer. However, the efficacy of gemcitabine against pancreatic cancer stratified by nodal involvement is unclear. In this...

Full description

Bibliographic Details
Main Authors: Chen Liu MD, PhD, He Cheng MD, Kaizhou Jin MD, PhD, Zhiyao Fan MD, Yitao Gong MD, Yunzhen Qian MD, Shengming Deng MD, Qiuyi Huang MD, Quanxing Ni MD, Xianjun Yu MD, PhD, Guopei Luo MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2020-04-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/1073274820915947

Internet

https://doi.org/10.1177/1073274820915947

Similar Items